Cagrilintide + Semaglutide (2.5mg + 2.5mg)
Co-formulated research blend pairing long-acting amylin analogue Cagrilintide (2.5 mg) with GLP-1 receptor agonist Semaglutide (2.5 mg) for investigating dual satiety and pancreatic endocrine signaling.
Scientific Profile & Research Key Points: Cagrilintide + Semaglutide
Co-formulated research blend pairing long-acting amylin analogue Cagrilintide (2.5 mg) with GLP-1 receptor agonist Semaglutide (2.5 mg) for investigating dual satiety and pancreatic endocrine signaling.
Active Batch Release Specifications (Lot SL-2026-113)
Analytical release verification for current Cagrilintide + Semaglutide (2.5mg + 2.5mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-113 | 2026-10-28 | Gradient RP-HPLC (Multi-Peak Resolution) + ESI-MS | ≥99.0% (Resolved Constituent Peaks) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile 0.9% Bacteriostatic Water or sterile neutral PBS buffer
Temperature & Stability
Store lyophilized at -20°C; keep reconstituted solution at 2°C–8°C and avoid freezing.
Cagrilintide + Semaglutide — Technical Questions & Answers
How are the individual constituents of Cagrilintide + Semaglutide verified in a single vial?
Because co-lyophilized blends contain multiple sequences with distinct retention times, Lot SL-2026-113 is evaluated via gradient RP-HPLC to resolve each constituent peak independently, paired with ESI-MS mass confirmation (4409.04 g/mol & 4113.58 g/mol).
How do you calculate working stock aliquots for a multi-component blend like Cagrilintide + Semaglutide?
Calculate each active constituent separately based on its labeled mass ratio (2.5mg + 2.5mg) divided by total diluent volume added. For example, adding 2.0 mL of sterile diluent yields proportional mg/mL concentrations for every component simultaneously.
What primary pathways are investigated using Cagrilintide + Semaglutide?
Investigators study Cagrilintide + Semaglutide in Dual Amylin/Calcitonin (AMYR/CTR) + GLP-1R agonism models. Primary published literature context: Frias J.P. et al., The Lancet (2023) — Co-administration of cagrilintide and semaglutide in metabolic models (PMID: 37364590). All lots are supplied strictly for in-vitro laboratory experimentation.
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
SLU-PP-332: Synthetic Pan-ERR Agonist Chemistry, DMSO Solubility & Mitochondrial Biogenesis
Analytical profile of small-molecule pan-ERR agonist SLU-PP-332 (CAS 303760-60-3): nuclear receptor EC50 selectivity, mitochondrial respiration models, and DMSO stock preparation.
Cagrilintide vs Retatrutide: Amylin/Calcitonin Receptors vs Triple Incretin Agonism
Biochemical comparison of long-acting amylin analogue Cagrilintide (AM833) against triple incretin agonist Retatrutide and dual-pathway Cagrilintide + Semaglutide combinations.
Survodutide vs Mazdutide vs Retatrutide: Dual GLP-1/Glucagon and Triple Agonist Biochemistry
Comparative receptor pharmacology of Survodutide (BI 456906), Mazdutide (IBI362), and Retatrutide (LY3437943): GLP-1R/GCGR/GIPR potency ratios and stability.